# US 2021/0332098 A1 · Nsp-interleukin-10 proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332098 A1
- Document ID: US20210332098A1
- Status: Published application
- Kind: A1
- Application number: 17/366,648
- Filed: 2021-07-02
- Published: 2021-10-28
- Earliest claimed: 2018-12-05
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education
- Applicants: University of Pittsburgh-of the Commonwealth System of Higher Education
- Inventors: Yangzi Jiang; Rocky S. Tuan
- Web page: https://patentgrep.com/patent/US20210332098A1

## CPC

- C07K 14/5428: {IL-10}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/48: Nerve growth factor [NGF]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/41: containing a Myc-tag
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are Nsp-IL10 polypeptides comprising an Nsp polypeptide and an IL10 polypeptide. In some embodiments, Nsp-IL10 polypeptide is capable of activating an NGF signaling pathway, an IL10 signaling pathway, or both. Also disclosed are methods for treating a disease comprising administering an Nsp-IL10 polypeptide. The methods include treating diseases associated with joint inflammation, such as osteoarthritis.

## Claims

### Claim 1

An Nsp-IL10 polypeptide comprising an Nsp polypeptide and an IL10 polypeptide.

### Claim 2 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, wherein the Nsp polypeptide and the IL10 polypeptide are directly linked.

### Claim 3 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, wherein the Nsp polypeptide comprises SEQ ID NO: 2.

### Claim 4 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, wherein the IL10 polypeptide comprises SEQ ID NO: 4.

### Claim 5 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, further comprising a signal peptide.

### Claim 6 (depends on 5)

The Nsp-IL10 polypeptide of claim 5, wherein the signal peptide comprises SEQ ID NO: 5.

### Claim 7 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, further comprising one or more linkers.

### Claim 8 (depends on 7)

The Nsp-IL10 polypeptide of claim 7, where the one linker is between the Nsp polypeptide and the IL10 polypeptide.

### Claim 9 (depends on 7)

The Nsp-IL10 polypeptide of claim 7, wherein the linker comprises SEQ ID NO: 6.

### Claim 10 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, wherein the IL10 polypeptide comprises an amino acid sequence having at least 60% identity with SEQ ID NO: 4.

### Claim 11 (depends on 1)

The Nsp-IL10 polypeptide of claim 1, wherein the polypeptide comprises SEQ ID NO: 7.

### Claim 12 (depends on 1)

A polynucleotide encoding the polypeptide of claim 1.

### Claim at position 13

-19. (canceled)

### Claim 20

A kit comprising a vector comprising a polynucleotide sequence encoding an Nsp-IL10 polynucleotide operably linked to a promoter, wherein the Nsp-IL10 polynucleotide comprises an Nsp polynucleotide and an IL10 polynucleotide.
